RJA
TFFP

Raymond James & Associates’s TFF Pharmaceuticals, Inc. Common Stock TFFP Stock Holding History

Raymond James & Associates’s Portfolio TFFP Stock Details TFFP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1,898
Closed -$193K – 4088
2022
Q3 		$193K Buy
1,898
+136
+8% +$18.4K ﹤0.01% 3458
2022
Q2 		$249K Buy
1,762
+348
+25% +$48.6K ﹤0.01% 3360
2022
Q1 		$223K Sell
1,414
-60
-4% -$9.69K ﹤0.01% 3611
2021
Q4 		$327K Buy
1,474
+2
+0.1% +$387 ﹤0.01% 3381
2021
Q3 		$284K Buy
1,472
+581
+65% +$123K ﹤0.01% 3456
2021
Q2 		$214K Buy
+891
New +$244K ﹤0.01% 3647
2020
Q3 		– Sell
-493
Closed -$71K – 3715
2020
Q2 		$71K Buy
+493
New +$62.3K ﹤0.01% 3339

Other funds holding TFFP

ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
CC
Carlson Capital Dallas, Texas $318M AUM 27.64% 1-Year Est. Return
DS
DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return
GS
Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return
SC
Sepio Capital Salt Lake City, Utah $1.84B AUM 18.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Raymond James & Associates's TFFP Position: Q4 2022 in Review

Raymond James & Associates sold out of TFF Pharmaceuticals, Inc. Common Stock (TFFP) in Q4 2022, closing a stake of 1,898 shares — an estimated $193K sold.

Raymond James & Associates first reported a position in TFFP in Q2 2020 and held it in 7 quarters. The position peaked at $327K in Q4 2021. 41 funds tracked by Wall St. Rank hold TFFP as of Q4 2022.

  • Raymond James & Associates reported no remaining TFF Pharmaceuticals, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Raymond James & Associates sold 1,898 TFF Pharmaceuticals, Inc. Common Stock shares in Q4 2022, an estimated $193K.
  • Raymond James & Associates first reported a position in TFF Pharmaceuticals, Inc. Common Stock in Q2 2020 and held it in 7 quarters.
  • Raymond James & Associates's TFF Pharmaceuticals, Inc. Common Stock position peaked at $327K in Q4 2021.
  • 41 funds tracked by Wall St. Rank held TFF Pharmaceuticals, Inc. Common Stock as of Q4 2022.

Based on Raymond James & Associates's 13F filing for Q4 2022, filed 8 Feb 2023.